[ad_1] STOCKHOLM, Nov. 18, 2025 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®) at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held […]
Tag: BioArctic
Leqembi® approved for IV maintenance treatment in the United Kingdom
[ad_1] STOCKHOLM, Nov. 13, 2025 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi (lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing for the […]
Leqembi® approved for IV maintenance treatment in the United Kingdom
[ad_1] STOCKHOLM, Nov. 13, 2025 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi (lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing for the […]
Interim Report for the period July
[ad_1] STOCKHOLM, Nov. 13, 2025 /PRNewswire/ — Broadening our portfolio with new projects and partnerships Events during the third quarter 2025 New data on lecanemab were presented at the AAIC-congress focused on long-term efficacy and […]
Invitation to presentation of BioArctic’s third quarter report for July
[ad_1] STOCKHOLM, Nov. 4, 2025 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s third quarter report for July – September 2025 on Thursday, November 13, 2025, at 08:00 a.m. CET. […]
